Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, September 6, 2026

Back to today

Titan Mining Q2 Update

Titan Mining reported Q2 revenue of $25.7 million and adjusted EBITDA of $9.6 million as zinc output rose, while advancing its Kilbourne graphite project and germanium recovery.

TII $284M
Sylence Capital 4 clicks

From X

@eriksen_tim 1 click

Tim Eriksen on X

Is $EVC is a classic case of thesis drift for its investors? It was all about sequential hypergrowth (with a supposed SOTP margin of safety). Mgmt said Q3 will be below Q2. Now the thesis is about strong year over year growth. What happens in a few quarters when year over year growth is gone, or is low single digits? Is this really a seasonal business? For me it was a small position due to the nature of the situation. Q2 growth was lighter than I expected so I was selling after hours and have fully exited.
@KEDM_COM

KEDM.com on X

SEACOR Marine $SMHI has launched a strategic review, looking for value maximizing transactions – tough, clearly preferably a full sale. This comes after a ton of pressure from Pointillist (the largest shareholder), which argued SMHI’s market cap massively undervalues a fleet. Their thesis: the offshore cycle has fully recovered, but SMHI’s equity still trades at well below its $22/share broker appraised value. Seacor remains weighed down by high interest costs, G&A expenses, and subpar utilization, forcing asset sales to bolster liquidity. The premium PSV fleet alone should be worth ~$11/ share, with FSVs and Middle East liftboats pushing embedded value to $15/share+, vs. today’s price.
@BlueDuckCap 1 click

BDC on X

$XGN remains a top holding for us. Even after the big move higher post a beat and raise Q2, the shares trade for a material discount versus comps. The discount is silly. Especially when we consider that they are launching a new marker for Myositis. XGN tells us that Rheumatologists are BY FAR requesting a precise diagnostic for Myositis more than any other condition. The reason is because Myositis is treatable if caught early, but problematic if not. "this is the #1 asked for product amongst our rheumatologists clinical base... it's not even close to the #2 asked for offering" $XGN trades for 2x 2026 revenues. Comps go for 10x.

Investor Letters

All letters

EVC Update

EVC reported a solid second quarter and outlook.

EVC $666M
Nat Stewart - Stock Picking Newsletter 15 clicks

IEH Corporation: Research Note

IEH Corporation won $6.5 million of APKWS orders, lifting backlog above $45 million as defense connector demand drives capacity expansion.

IEHC $74M
Atrium Research - Equity Research 1 click

Late August 2026 Random Ramblings

Higher rates could compress equity multiples and raise AI data center lease costs, while UWMC and Cogent raise questions about CEO-driven…

CCOI $377M
Yet Another Value Podcast 13 clicks

The Verra Sneerer (NASDAQ:VRRM)

Verra Mobility renewed Hertz tolling management for five years. AutoKinex lets rental customers buy tolling, fuel and protection products…

VRRM $458M
The Oak Bloke 6 clicks
TOYO · short

Toyo CO LTD

TOYO CO LTD is the target of a short thesis.

TOYO $181M
Value Investors Club

Portillo’s: Strategic Reset

Portillo’s reset follows weak Texas unit economics, cutting next year’s openings to five from roughly 10 annually and shrinking store…

PTLO $267M
TSOH Investment Research

Publications we follow

Every publication on this site, hand-picked.

108 publications

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 36 of 186

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

72 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.